. 2020 Feb 6;10(2):248. doi: 10.3390/biom10020248

Table 1.

List of promising anticancer marine products from bacteria, actinobacteria, and cyanobacteria studied in pre-clinical studies and reviewed in this work.

Compound Name	Marine Organism	Species Name	Active Derivative	Cancer Model	In Vitro	In Vivo	IC50 In Vitro	Route of Administration In Vivo	Dose Used In Vivo	Ref.
Pyrroloformamide	Actinobacteria	Streptomyces sp.	Pyrrolinonodithiol	Human prostate cancer cell line PC-3M	✓	✗	1.67 nM	N/A	N/A	[20]
Cromomycin A2	Actinobacteria	Streptomyces sp.	Aureolic acid	Human melanoma cell line MALME-3M	✓	✗	16.7 nM	N/A	N/A	[21]
Anthracyclinone 4	Bacteria	Micromonospora sp.	Anthracyclinone	Human colon adenocarcinoma cell line HCT-8	✓	✗	6.2 µM	N/A	N/A	[22]
Coibamide-A	Cyanobacteria	Leptolyngbya sp.	Cyclic depsipeptide	Human lung cancer cell line NCI-H460 and mouse neuro-2a cells	✓	✗	< 23 nM	N/A	N/A	[23]
Lucentamycins A	Bacteria	Nocardiopsis lucentensis	Non-ribosomal peptides	Human colon carcinoma cell line HCT-116	✓	✗	0.20 µM	N/A	N/A	[25]
Mixirins A, B & C	Bacteria	Bacillus sp.	Non-ribosomal peptides	Human colon carcinoma cell line HCT-116	✓	✗	A: 0.68, B: 1.6, and C: 1.3 mg/mL	N/A	N/A	[26]
Ohmyungsamycins A&B	Actinobacteria	Streptomyces sp.	Non-ribosomal peptides	Human colon carcinoma cell line HCT-116	✓	✗	A: 0.359 µM, B: 12.4 µM	N/A	N/A	[27]
				Human lung cancer cell line A549	✓	✗	A: 0.551 µM, B: 15.6 µM	N/A	N/A
				Human stomach cancer cell line SNU-638	✓	✗	A: 0.532 µM, B: 13.5 µM	N/A	N/A
				Human triple negative breast cancer cell line MDA-MB-231	✓	✗	A: 0.688 µM, B: 12.7 µM	N/A	N/A
				Human hepatic adenocarcinoma cancer cell line SK-HEP-1	✓	✗	A: 0.816 µM, B: 16.8 µM	N/A	N/A
Urukthapelstatin A	Actinobacteria	Mechercharimyces asporophorigenens	Non ribosomal peptides	Human lung cancer lines A549, DMS114, and NCIH460	✓	✗	A519: 12 nM	N/A	N/A	[28]
				Human ovarian cancer cell lines OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SK-OV3	✓	✗	0.828–0.846 nM for the rest	N/A	N/A
				Human breast cancer cell line MCF-7	✓	✗	0.828–0.846 nM for the rest	N/A	N/A
Symplostatin 1	Cyanobacteria	Symploca hydnoides	Linear pentapeptide	Human colon adenocarcinoma cell line LoVo	✓	✗	0.34-0.50 nM	N/A	N/A	[16]
				HeLa-derived cell line KB	✓	✗	0.15-0.20 nM	N/A	N/A
				Early stage colon adenocarcinoma #38	✗	✓	N/A	i.v.	3 mg/Kg
				Early stage mammary adenocarcinoma 16/C	✗	✓	N/A	i.v.	1.25 mg/Kg
				Human breast cancer cell line MDA-MB-435	✓	✗	0.15 nM	N/A	N/A	[17]
				Human ovarian cancer cell line SK-OV-3	✓	✗	0.09 nM	N/A	N/A
				Multidrug resistant human ovarian cancer cell line NCI/ADR	✓	✗	2.9 nM	N/A	N/A
				Early stage colon adenocarcinoma #38	✗	✓	N/A	i.v.	3 mg/Kg
				Early stage mammary adenocarcinoma 16/C	✗	✓	N/A	i.v.	0.5, 0.25 mg/Kg
TZT-1027	Cyanobacteria	Symploca sp.	Synthetic tetrapeptide. Dolastatin 10 derivative	Murine leukemia P338, melanoma B16, colon cancer colon 26 and sarcoma M5076 allografts	✗	✓	N/A	i.p. and i.v.	0.125–3 mg/Kg	[18]
TZT-1027	Cyanobacteria	Symploca sp.	Synthetic tetrapeptide. Dolastatin 10 derivative	Human lung cancer LX-1 and breast carcinoma MX-1 xenografts	✗	✓	N/A	i.v.	0.5–2 mg/Kg	[18]